SCHEMBL1887656

SCHEMBL1887656

CCOC(=O)n1nc2c(c1NC(=O)c1ccc(N3CCN(C)CC3)cc1[N+](=O)[O-])CN(C(=O)OC(C)(C)C)CC2(C)C

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
ALDH1A1 P00352 4/20 0.39
LMNA P02545 3/20 0.39
SIRT6 Q8N6T7 6/20 0.38
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
WDR5 P61964 1/20 0.33
HTR6 P50406 1/20 0.33
BCL2 P10415 1/20 0.33
BCL2L1 Q07817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1893808 0.93 MAPT (0.38) MAPTALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL1373769 0.89 SIRT6 (0.39) MAPTALDH1A1LMNASIRT6POLB
SCHEMBL2453090 0.86 MAPT (0.34) MAPTALDH1A1LMNAPOLBSMN1; SMN2
SCHEMBL1891834 0.86 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2L3MBTL1MEN1
SCHEMBL1892811 0.85 L3MBTL1 (0.35) MAPTALDH1A1LMNAMAPK1L3MBTL1
SCHEMBL4793930 0.83 SIRT6 (0.42) MAPTALDH1A1LMNASIRT6POLB
SCHEMBL2678984 0.83 SIRT6 (0.41) MAPTALDH1A1LMNASIRT6POLB
Hydrochloric Acid SCHEMBL2678981 0.83 SIRT6 (0.40) MAPTALDH1A1LMNASIRT6POLB
SCHEMBL1893236 0.82 IGF1R (0.41) MAPTLMNASIRT6POLBMAPK1
SCHEMBL1371503 0.82 SIRT6 (0.42) MAPTALDH1A1LMNASIRT6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 MAPT 2600/4885ALDH1A1 2295/4885LMNA 3253/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 MAPT 2600/4885ALDH1A1 2295/4885LMNA 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.